FDA actions in brief, October 2008 (Cancidas, Aloxi, Vidaza)
Recent FDA approvals and indications (through October 2008) related to Cancidas, Aloxi, and Vidaza.
Caspofungin (Cancidas, Merck) was approved for use in pediatric patients aged 3 months to 17 years as empiric therapy for presumed fungal infections in febrile, neutropenic patients and for the treatment of candidemia and other Candida infections including intra-abdominal abscesses, peritonitis, and pleural space infections, as well as for the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Palonosetron capsules (Aloxi, Eisai/Helsinn Healthcare) were approved for the prevention of chemotherapy-induced nausea and vomiting.
The labeling for azacitidine (Vidaza, Celgene) was expanded to reflect new overall survival data from the AZA-001 survival study in patients with higher-risk myelodysplastic syndromes (MDS). This agent is approved for the treatment of all 5 subtypes of MDS.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
